JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Recursion Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

5.71 -0.17

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.63

Max

5.84

Schlüsselkennzahlen

By Trading Economics

Einkommen

31M

-172M

Verkäufe

4.4M

19M

Gewinnspanne

-899.843

Angestellte

800

EBITDA

44M

-148M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+3.48% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

356M

2.9B

Vorheriger Eröffnungskurs

5.88

Vorheriger Schlusskurs

5.71

Nachrichtenstimmung

By Acuity

100%

0%

357 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Okt. 2025, 20:49 UTC

Ergebnisse

Correction to Thermo Fisher Article on Oct. 22

23. Okt. 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23. Okt. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. Okt. 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23. Okt. 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23. Okt. 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23. Okt. 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23. Okt. 2025, 22:49 UTC

Akquisitionen, Fusionen, Übernahmen

How Trump Sparked a New Era of State Capitalism -2-

23. Okt. 2025, 22:49 UTC

Akquisitionen, Fusionen, Übernahmen

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23. Okt. 2025, 22:17 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23. Okt. 2025, 21:41 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23. Okt. 2025, 21:05 UTC

Ergebnisse

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23. Okt. 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

23. Okt. 2025, 20:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

23. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. Okt. 2025, 20:35 UTC

Ergebnisse

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23. Okt. 2025, 20:28 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23. Okt. 2025, 20:15 UTC

Market Talk
Ergebnisse

Global Commodities Roundup: Market Talk

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q Adj EPS $1.71

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q Sales $5.52B

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q EPS $1.67

23. Okt. 2025, 20:09 UTC

Ergebnisse

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23. Okt. 2025, 20:07 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

23. Okt. 2025, 20:07 UTC

Market Talk
Ergebnisse

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23. Okt. 2025, 20:07 UTC

Ergebnisse

Blackstone Looks to IPOs for Investment Exits -- Update

23. Okt. 2025, 20:05 UTC

Ergebnisse

Intel 3Q Gross Margin 38.2% >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel: 4Q Guidance Excludes Altera >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel Sees 4Q Adj EPS 8c >INTC

Peer-Vergleich

Kursveränderung

Recursion Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

3.48% Vorteil

12-Monats-Prognose

Durchschnitt 5.95 USD  3.48%

Hoch 8 USD

Tief 3 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Recursion Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

1

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

4.15 / 4.75Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

357 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat